Joe Pantagnous
Analyst, HC Wainwright
Replay available
BioLineRX (TASE:BLRX) Q2 2020 earnings call, held 2020-08-06. Watch the replay and read the transcript on 6ix.

On 6ix: 6ix.com/event/biolinerx-ltd-blrx-q2-2020-earnings-call
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:00 Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx second quarter 2020 results conference call. All participants are present in a listen-only mode. Following the management's formal presentation, instructions will be given for the question and answer session. For operator assistance during the conference, please press star zero. I would now like to turn the call over to Timothy McCarthy of LifeSciAdvisors to read the Safe Harbor Statement. Tim, please go ahead.
0:24 Thank you, Operator. Before turning the call over to management, I would like to make the following remarks concerning forward-looking statements. All statements in this conference call, other than historical facts, are indeed forward-looking statements. The words anticipate, believe, estimate, expect, intend, guidance, confidence, target, project, and other similar expressions are used typically to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and may involve and are subject to certain risks and uncertainties and other factors that may affect BioLineRx's business, financial condition and other operating results. These include but are not limited to the risk factors and other qualifications contained in BioLineRx's annual report on Form 20F, quarterly reports filed in the 6K and other reports filed by BioLineRx with the SEC to which your attention is directed.
1:17 Actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements. BioLineRx expressly disclaims any intent or obligation to update these forward-looking statements. At this time, it is now my pleasure to turn the call over to Mr. Phil Serlin, Chief Executive Officer of BioLineRx.
1:38 Thank you, Tim, and good morning, everyone. And thank you for joining us on our second quarter earnings conference call today. Earlier this morning, we issued our Q2 results press release. A copy of which is available in the investor relations section of our website. It was also filed as a 6K. I will begin with some brief prepared remarks, then Mali Zeevi, our Chief Financial Officer, will provide a short discussion of our financial results. We will then open up the call to your questions. Also joining the call for Q&A are Abby Weinstein, our Vice President, Clinical Development, and Ella Sorani, our Vice President, Research and Development. During the second quarter, we continue to advance our clinical programs towards important and meaningful data readouts that are anticipated over the next few months.
2:28 And while some timelines have changed very modestly as a result of COVID-19 and other factors, we look forward to a catalyst-rich second half of the year from Metixa Fortide, formerly known as BL8040, our lead clinical candidate. Recall that Metixa Fortide is currently being evaluated in multiple late-stage trials across a range of cancer indications. At this point, I will provide an update on our motixifortide development programs as well as our second clinical candidate, the anti-cancer vaccine, AGI-134. Beginning with late-stage pancreatic cancer, or PDAC, recall that we are currently evaluating motixifortide in combination with Keytruda and chemotherapy in a Phase IIa clinical trial known as the COMBAT-Kino-202 trial, under a clinical trial collaboration with Merck.
3:19 As you probably know, PDAC is among the most difficult cancers to treat, and patients with this diagnosis have historically had very poor prognoses. More than 50% of PDAC patients are first diagnosed with advanced stage four disease, due mainly to the fact that this cancer is asymptomatic while it is metastasizing. In addition, immunotherapy has had a very limited effect in PDAC, both alone and in combination. So this is clearly a cancer indication with a substantial unmet medical need. During the fourth quarter of 2019, we announced encouraging preliminary data from this triple combination arm. Briefly recapping the results of 22 evaluable patients at that time, the combination demonstrated a 32% overall response rate, a 13.6 confirmed overall response rate, and a 77% disease control rate.
4:13 disease control defined as patients with partial responses or stable disease. Out of the seven partial responders at that time, five were still on treatment with a maximum treatment time of over 330 days, and four responders showed a reduction in tumor burden of greater than 50%. In addition, the median duration of clinical benefit for the 17 patients exhibiting disease control was 7.8 months. This data was later published in Nature Medicine. In February, we completed enrollment of a total of 43 patients in the study and had previously guided to providing survival data in the middle of this year. However, as this is an event-driven study, the requisite number of events has not yet been reached. The data is still maturing, and we now expect to report full results, including overall survival, progression-free survival, and final overall response rate later in the second half of this year. We are pleased that as of today, there are still patients on study, and we hope this is an encouraging sign.
5:15 We look forward to announcing this important data as soon as we were able to do so. Turning now to stem cell mobilization, we continue to advance our Genesis Phase III study, and this continues to represent our most efficient path to registration. This study is a double-blind, placebo-controlled trial comparing metixifortide in combination with GCSF to GCSF alone. for the mobilization of stem cells used for autologous transplantation in multiple myeloma patients. The primary endpoint is the proportion of subjects mobilizing over six million CD34 positive cells per kilogram in up to two apheresis sessions. Recall that in the lead-in portion of the study, our analysis of the first 11 patients found that nine out of 11, 82% of the patients received the primary endpoint with one administration of BL8040 and up to two apheresis sessions, while eight out of 11 or 73% reached the threshold after only one apheresis session.
6:16 These are very compelling results and hold great promise for the 50 to 70% of multiple myeloma patients who are poor mobilizers. Based on those lead-in results in the first 11 patients, the DMC recommended that we move directly into the randomized portion of the study without the need for completing the full 30 patients in the lead-in period. The COVID-19 pandemic has had an effect on recruitment. On the other hand, we have seen a significantly lower dropout rate than we had anticipated when calculating the original sample size. As a result of these factors, we have made the decision to conduct an interim analysis on approximately 65% of the original trial sample size later in the second half of this year, for which the recruitment is nearly complete.
7:13 Should the interim analysis demonstrate that the primary endpoint has been reached, we expect to announce the immediate termination of further enrollment. In order to maintain study blinding, top line results, including 100 days of patient follow-up subsequent to transplantation, will be announced in the first half of next year. If the interim analysis demonstrates that the primary endpoint has not yet been reached, study recruitment will continue to completion of the full target enrollment of 177 patients. Should this be the case as mentioned, we anticipate that the ongoing COVID-19 pandemic will have some impact on patient recruitment and taking this into consideration, we would expect to report top line data under this scenario in the second half of next year.
8:00 Moving on to the Phase IIb BLAST study of metixifluorotide consolidation AML. This study is a randomized, one-to-one, double-blind, placebo-controlled study with two arms, BL8040 plus cytarabine and placebo plus cytarabine. The primary endpoint is relapse-free survival. Our collaboration partners for this study, the German Leukemia Alliance, will be conducting an interim analysis on 128 out of 194 planned study subjects, all of whom have completed the full 18 months of follow-up in the study. The interim analysis will also include a futility analysis, and accordingly, the study will stop in the event of overwhelming superiority or futility. Otherwise, the DMC will make a recommendation regarding study continuation.
8:49 Consistent with our prior guidance, we anticipate reporting results from the interim analysis in the back half of this year as well. If positive, these results together with the meaningful proof of concept data announced in our previously conducted Phase 2A study in relapsed refractory AML would provide strong rationale for continued development in this indication, and we plan to meet with the regulators to discuss the optimal development path forward in the AML setting. If the study is not terminated due to futility or overwhelming superiority as mentioned, the DMC will make a recommendation recording study continuation in which case the number of subjects will be increased by eight patients to 202 patients. And in that scenario, the estimated completion date will be in 2023 at the earliest.
9:38 Before turning to our second clinical candidate, AGI-134, I would like to briefly comment on COVID-19 and the opportunity that it presents us. As we previously disclosed last quarter, but it is worth reiterating, we are currently evaluating motixifortide as a potential therapy for for COVID-19 induced inflammatory lung disorders, including acute respiratory distress syndrome, or ARDS. In this regard, substantial data is emerging regarding the involvement of neutrophils and macrophages in the development of COVID-19 lung symptoms, including severe complications such as ARDS, as well as the key involvement of CXCR4 as the primary mediator of those cells in the inflamed alveolar tissue of the lungs.
10:25 Our hypothesis is that motixifortide may succeed in modulating neutrophils and macrophages via CXCR4 inhibition, thus reducing their retention in the lungs, potentially resulting in improved morbidity and mortality. We are currently evaluating the optimal pathway to obtain initial clinical data in the shortest time possible, and we will, of course, keep you apprised of our progress. Now turning to AGI134. Our second clinical candidate, AGI-134, is a synthetic alpha-gal glycolipid immunotherapy in development for solid tumors. AGI-134 harnesses the body's preexisting, highly abundant anti-alpha-gal antibodies to induce a hyperacute, systemic, specific anti-tumor response to the patient's own tumor neoantigens.
11:17 This response not only kills the tumor cells at the site of injection, but also brings about a durable follow-on anti-metastatic immune response. We are evaluating AGI-134 in an open-label Phase I-IIa study in patients with unresectable solid tumors. The study is designed to evaluate the safety and tolerability of AGI-134 at the recommended dose in multiple solid tumor types, to evaluate a wide range of biomarkers, and to validate AGI-134's mechanism of action. We will also assess clinical and pharmacodynamic parameters. Recall that in September 2019, we announced positive safety data, and later that same month, we moved quickly to initiate part two, which is a dose expansion phase.
12:02 In part two, we are assessing the efficacy of AGI-134 using clinical and pharmacodynamic parameters. The trial is being carried out in the UK, US, and Israel, all of which have been hard hit by the COVID-19 pandemic. Approximately four months ago, the decision was made to temporarily suspend enrollment in this trial, which we continue to expect will lead to an approximate nine-month delay. We are now gradually resuming enrollment activities and we expect to report data in the second half of 2021. This is unchanged from the revised timing that we introduced last quarter. This delay does not dampen our enthusiasm for the molecule, which in preclinical studies has demonstrated an ability to drive primary tumor regression while preventing the growth of untreated distal secondary tumors.
12:53 It also triggers a vaccine effect that may prevent the development of future metastases. I would now like to turn the call over to Mali Zeevi, our CFO, who will give a brief overview of our key second quarter financial statement items. Mali, please go ahead.
13:09 Thank you, Phil. In our financial discussion, we will only go over a few significant items on this call. Research and development expenses and cash. Therefore, let me invite you to review the filings we made this morning, which contain our financials, operating and financial review, and press release for additional information. Research and development expenses for the six months ended June 30, 2020, were $10.1 million dollars, An increase of $0.4 million, or 3.8%, compared to $9.7 million for the comparable period in 2019. The increase resulted primarily from higher expenses associated with the MOTIC-supported combat and genesis clinical trials, offset by a decrease in expenses associated with the AGI-134 study.
14:03 Turned into cash, the company held $27.3 million, of cash, cash equivalents, and short-term bank deposits as of June 30, 2020. During the second quarter, we completed two registered direct offerings that raised aggregate gross proceeds of $13.4 million. We reiterate our previous cash guidance that our current resources are sufficient to fund our operations through our most significant clinical milestones. And with that, I'll turn the call back over to Phil.
14:38 Thank you, Mali. In closing, as is our custom, I would like to take a few moments to summarize our three key data milestones for this year. One. Full results, including overall survival, progression-free survival, and full overall response rate data from the COMBAT Keynote 202 Phase 2A Triple Combination Study in the second half of this year. Two. Interim analysis of our Phase III Genesis Registrational Study in Stem Cell Mobilization in the second half of this year. If the primary endpoint is reached, we would immediately announce cessation of recruitment at that time and would expect to have full top-line data in the first half of 2021. Otherwise, if the primary endpoint is not met in the interim analysis, we would complete full recruitment of the study and would anticipate full top-line data in the second half of next year.
15:29 and three, interim analysis from the BLAST Phase 2b AML consolidation study during the second half of 2020, unchanged from prior guidance. Notwithstanding the modest changes to certain timelines as set forth above, we are on track to achieve multiple important and potentially value creating data catalysts in the second half of this year. We are pleased with our continued progress, particularly in light of the disruptions caused by the pandemic, and I look forward to providing future updates. With that, we have now concluded the formal part of our presentation. Operator, we will now open up the call to questions. Thank you. Ladies and gentlemen, at this time, we will begin the question and answer session. If you'd like to ask a question, please press star 1.
16:14 To withdraw your question, please press star 2. If you are using speaker equipment, kind of lift the headset for pressing the numbers. Your questions will be pulled in the order they are received. Please stand by while we pull for your questions. The first question is from Joe Pantaginous of HCUN, right? Please go ahead.
16:34 Hi, everyone. How's everything? Hope you're all doing well in this current environment. Thanks for taking the question. Two questions, if you don't mind. First, regarding combat, just wanted to see, hopefully it does have to do with patients being on the study longer, that the timelines have been pushed out a little bit, so we'll just keep going. Our fingers crossed on that, but just wanted to ask directly on any impacts on COVID directly on combat with regard to losing any patient.
17:04 Yeah, hi. Hi, Joe. It's good to speak to you, and I hope you're doing well. Yeah, so there has been no impact of COVID-19 on the combat study. As we mentioned, it's fully recruited. We completed recruitment in February already. and the patients are still coming in based on their scheduled appointments. You know, since pancreatic cancer is such a difficult indication, you know, the patients are less likely to avoid coming to the hospital in order to get their treatment. So, like I said, it hasn't had much of an impact at all.
17:43 No, that's great. Thanks for that. And then just my second question has to do with Genesis. So definitely an intriguing announcement today with regard to the interim analysis. So I guess my question would revolve around your regulatory discussions around this interim and what the potential statistical hit would be for introducing this interim.
18:02 Yeah, so let me just first, I mean, you know, just I want to reiterate. We have, you know, this interim analysis is something, I mean, we saw already, you know, earlier in the year already that That the dropout rate was significantly lower than expected. Due to the fact that we've seen some difficulty with the recruitment, it brought us to the conclusion that it makes sense that we don't think that there's a big risk in performing an interim analysis. As far as I know, we don't believe that there would be much of a statistical hit
18:44 at all. Only a minimal penalty.
18:46 Only a minimal penalty. And we've already filed the protocol for the interim analysis. It's been approved by the regulatory authorities, the statistical analysis plan as well. And as I've mentioned also, we're almost done with the recruitment. So there's very little to stop
19:07 The next question is from Mark Bredenbach of Oppenheimer. Please go ahead.
19:21 Hey, thanks for taking my questions. Phil, I guess I'm just wondering if a smaller trial size would still satisfy the safety database requirement for product registration in Genesys. And also it would be helpful if you can remind us what the original powering assumptions were for Genesis and how a potentially reduced trial size could impact that powering.
19:44 Yes, so as far as I'll take the safety aspect and then I'll turn it over to Abby for the second part of the question. You know, as you know, this trial has been going on for a while. In the meantime, we have increased capacity. The study, the combat study, we did a second norm in the combat study. And so we feel also there's been more patients as well in the AML study. So we feel that this will have little to no impact as far as the amount of patients necessary from a safety perspective with the FDA. As far as, can you repeat the second part? Did you hear the second part of the question? Can you repeat the second part of the question, please, Mark?
20:27 Sure, just if you can remind us what the original powering assumptions were for Genesis and how potentially reducing the trial size would impact powering.
20:38 Mark, I will take this question. Actually, we cannot disclose the power for the study. However, as you know, we power a codemic to a Phase III trial for registration and with the requirement of the FDA. Basically, the protocol amendment with the interim analysis was submitted to the FDA and approved by the FDA. Therefore, we don't see any issue in this regard with the number of patients that we suggest for the interim analysis. Actually, again, the idea of this interim analysis is mainly based on the fact that we didn't have The percentage of dropout rate that we calculate in the beginning, therefore, we don't believe that there will be any effect on the power of the study or in the number of the successful of the study.
21:33 Yeah, I mean, I'd like to also maybe emphasize, you know, from our perspective, this is one of our, you know, most important milestones. And this is our first registration trial. and I want to assure you that we would not be doing anything to jeopardize the study in any way and so we feel very comfortable going forward with the interim analysis because of the significant decrease in the dropout rate.
22:04 Okay, and maybe one final one from me on combat keynote 202. Should we be expecting the PFS and OS data to be presented at a major medical meeting in the fall, or are these results simply going to be delivered by a press release?
22:22 We haven't made a decision yet. We're obviously looking at conferences. It's hard to plan the study while it's still ongoing as far as when we're going to be able to do a data cut for a particular conference. I think that we felt last December it made sense. We had just had enough data for half of the patients. I think we feel very strongly that we need to complete the study as soon as possible, get the results, make sure that we've done everything to clean the data properly, et cetera, et cetera. And so we haven't made a decision yet as far as when and which conference, but obviously we would like to present at a conference.
23:07 Okay, thank you. If there are any additional questions, please press star 1. To withdraw your question, please press star 2. Please stand by while we poll for your questions. We have a follow-up question from Joe Pentagonis of HCWinry. Please go ahead.
23:27 Hey, guys. Thanks for taking the follow-up. I just wanted to get back on regarding the statistical analysis plan for Genesis that you submitted to the FDA. I guess I would ask it this way. What do you consider it? Was it a standard discussion to be able to implement these changes, or did you have to invoke on any of FDA's recent commentary that they would be, say, how would I put it, a little forgiving with regard to COVID impacts on studies?
23:58 No, we actually didn't have any problems in regard with the COVID because we don't have any patients that have major issues in regard to the COVID. There are sites who stopped the recruitment because of this issue, but there are some considerations that do not affect the primary endpoint and the principal secondary endpoint on the study. We submit The interim analysis to the FDA. They approved the interim analysis. We submit the statistical analysis plan. They work with us also to allow this interim analysis to be done.
24:40 Fantastic. Thank you very much. There are no further questions at this time. Before I ask Mr. Phil Serlin to go ahead with his closing statement, I would like to remind participants that a replay of this call is scheduled to begin two hours after the conference. In the U.S., please call 1-888-782-4291. In Israel, please call 03-925-5921. Internationally, please call 972-3925-5921. Mr. Serlin, would you like to make your concluding statement?
25:17 Yes, I would. Thank you. That concludes our call this morning. I'd like to thank you again for your interest in BioLineRx, and we look forward to our next comprehensive update in November. Be safe and have a great day. Thank you. This concludes the BioLineRx second quarter 2020 conference call. Thank you for your participation. You may go ahead and disconnect.
Follow BioLineRX Ltd. into a list and get an email when it puts out news.
Analyst, HC Wainwright
Chief Executive Officer
LifeSci Advisors
Analyst, Oppenheimer & Co.
Chief Financial Officer
Vice President, Clinical Development